

Global Natural Killer (NK) Cell Therapeutics Market: Investment & Growth Opportunity Analysis, 2019-2028

Market Report | 2022-09-01 | 120 pages | RationalStat

AVAILABLE LICENSES:

- Single User License \$4570.00
- Multi User License \$6220.00
- Corporate License \$7870.00

Report description:

Global Natural Killer (NK) Cell Therapeutics Market: Investment & Growth Opportunity Analysis, 2019-2028

Market Introduction

The Global Natural Killer (NK) Cell Therapeutics market is estimated to grow at a robust CAGR of 51.8% during the forecast period of 2022-2028. The market growth is attributed to the increasing interest of the pharmaceutical industry players in cellular immunotherapy. NK cell therapeutics is anticipated to witness robust growth during the forecast period owing to its ability to fulfil unmet medical needs, overcome limitations associated with existing immunotherapies, and address complex and challenging targets.

The recent increase in the number of approvals received for cancer immunotherapies is considered to have added value to the NK cell therapeutic market. Moreover, market players are making efforts for the development of novel NK cell therapies which further gives a boost to the growth of the market. For instance, Under the agreement, Gilead would receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001. DF7001 is a TriNKET designed to activate and direct NK and cytotoxic T cell killing against cancer cells. The target of DF7001 is 5T4, a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC).

Market Segmentation

The global NK cell therapeutics market has been analyzed on the basis of application, end user, and region. On the basis of application, the market is segmented into Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, and Others. Cancer segment is expected to dominate the global market. Based on end user, the market is divided into hospitals and research centers & institutes. Geographically, the market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and Middle East & Africa. North America is dominating the global NK cell therapeutics market.

Market Structure and Competitive Landscape

Some of the prominent players that contribute significantly to the growth of the global NK cell therapeutics market include Nkarta, Inc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Affimed GmbH, Zelluna Immunotherapy, Nektar

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Therapeutics, XNK Therapeutics AB, ONK Therapeutics, Catarman Bio, MiNK Therapeutics, Celularity Inc., Artiva Biotherapeutics and others. These players adopt various strategies to reinforce their market share and gain a competitive edge over other competitors in the market. Partnerships and collaborations, research & development, and product launches are some of the strategies followed by industry players. Some of the key developments in the global NK cell therapeutics market include,

- In August 2022, Zelluna Immunotherapy announced an investment from Takeda Ventures, Inc. (TVI), the strategic investing arm of Takeda. TVI investment joins Zelluna's latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna's platform with additional programs reaching the preclinical stage.
- In January 2022, Takeda announced to acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (??) T Cell Engager Therapies Targeting Solid Tumors. Through the acquisition, Takeda would obtain Adaptate's antibody-based ?? T cell engager platform, including pre-clinical candidate and discovery pipeline programs.

Table of Contents:

Global NK Cell Therapeutics Market Analysis and Forecast 2019-2028

Table of Contents

- 1. Market Introduction
 - 1.1. Scope of Study
 - 1.2. Problem Statement
 - 1.3. Market Segmentation
- 2. Assumptions and Acronyms
- 3. Executive Summary
 - 3.1. Global Market in 2022
 - 3.2. Analyst Insights & Recommendations
 - 3.3. Growth Opportunities and Key Strategies
 - 3.4. Supply-side and Demand-side Trends
- 4. Research Methodology
- 5. Analysis of COVID-19 Impact and Road Ahead
- 6. Market Indicators and Background
 - 6.1. Macro-Economic Factors
 - 6.2. Forecasting Factors

Robust assessment of various factors including industrial performance, healthcare expenditures, industry players' expenditures, economic conditions, among others

 - 6.3. Supply Chain & Value Chain Analysis
 - 6.4. Industry SWOT Analysis
 - 6.5. PESTLE Analysis
 - 6.6. Porter's Five Forces Analysis
- 7. Government Laws and Industry Regulations
- 8. Global and Regional Market Dynamics
 - 8.1. Drivers
 - 8.2. Restraints
 - 8.3. Trends
 - 8.4. Opportunities
- 9. Global NK Cell Therapeutics Market: Key Investment Analysis
 - 9.1. By Key Industry Players
 - 9.2. By End User

9.3. By Therapeutic Application

9.4. By Region

9.5. M&A Activities

Robust assessment of major investments made by various industry players along with key therapeutic application areas, therapy type, and key region

10. Parent Market Overview: Global Healthcare & Life Sciences Market

11. Market Developments: Cell & Gene Therapy Products

11.1. By Region

11.1.1. North America

11.1.2. Latin America

11.1.3. Western Europe

11.1.4. Eastern Europe

11.1.5. Asia Pacific

11.1.6. Middle East & Africa

12. Clinical Trials Analysis

Exhaustive list of all the clinical trials sponsored by various industry players based on various cell types will be provided.

Moreover, it would also categorize the trials into IND submissions, Phase I, Phase II etc.

13. Segmental Analysis

13.1. Global NK Cell Therapeutics Market by Application

13.1.1. Segment Overview

13.1.1.1. Cancer

13.1.1.2. Gastrointestinal Diseases

13.1.1.3. Immunoproliferative Disorders

13.1.1.4. Others

13.2. Global NK Cell Therapeutics Market by End User

13.2.1. Segment Overview

13.2.1.1. Hospitals

13.2.1.2. Research Centers and Institutes

13.2.1.3. Others

13.3. Global NK Cell Therapeutics Market by Region

13.3.1. North America

13.3.2. Latin America

13.3.3. Western Europe

13.3.4. Eastern Europe

13.3.5. Asia Pacific

13.3.6. Middle East & Africa

14. Regional Analysis

14.1. North America NK Cell Therapeutics Market Analysis and Forecast 2019-2028

14.1.1. Regional Market Overview and Key Takeaways

14.1.2. North America NK Cell Therapeutics Market by Application

14.1.3. North America NK Cell Therapeutics Market by End User

14.1.4. North America NK Cell Therapeutics Market by Country

14.1.4.1. US

14.1.4.2. Canada

14.2. Latin America NK Cell Therapeutics Market Analysis and Forecast 2019-2028

14.2.1. Regional Market Overview and Key Takeaways

14.2.2. Latin America NK Cell Therapeutics Market by Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.2.3. □Latin America NK Cell Therapeutics Market by End User
- 14.2.4. □Latin America NK Cell Therapeutics Market by Country
 - 14.2.4.1. □Brazil
 - 14.2.4.2. □Mexico
 - 14.2.4.3. □Rest of Latin America
- 14.3. □Western Europe NK Cell Therapeutics Market Analysis and Forecast 2019-2028
 - 14.3.1. □Regional Market Overview and Key Takeaways
 - 14.3.2. □Western Europe NK Cell Therapeutics Market by Application
 - 14.3.3. □Western Europe NK Cell Therapeutics Market by End User
 - 14.3.4. □Western Europe NK Cell Therapeutics Market by Country
 - 14.3.4.1. □Germany
 - 14.3.4.2. □UK
 - 14.3.4.3. □France
 - 14.3.4.4. □Spain
 - 14.3.4.5. □Italy
 - 14.3.4.6. □Benelux
 - 14.3.4.7. □Nordic
 - 14.3.4.8. □Rest of Western Europe
- 14.4. □Eastern Europe NK Cell Therapeutics Market Analysis and Forecast 2019-2028
 - 14.4.1. □Regional Market Overview and Key Takeaways
 - 14.4.2. □Eastern Europe NK Cell Therapeutics Market by Application
 - 14.4.3. □Eastern Europe NK Cell Therapeutics Market by End User
 - 14.4.4. □Eastern Europe NK Cell Therapeutics Market by Country
 - 14.4.4.1. □Russia
 - 14.4.4.2. □Poland
 - 14.4.4.3. □Rest of Eastern Europe
- 14.5. □Asia Pacific NK Cell Therapeutics Market Analysis and Forecast 2019-2028
 - 14.5.1. □Regional Market Overview and Key Takeaways
 - 14.5.2. □Asia Pacific NK Cell Therapeutics Market by Application
 - 14.5.3. □Asia Pacific NK Cell Therapeutics Market by End User
 - 14.5.4. □Asia Pacific NK Cell Therapeutics Market by Country
 - 14.5.4.1. □China
 - 14.5.4.2. □Japan
 - 14.5.4.3. □India
 - 14.5.4.4. □South Korea
 - 14.5.4.5. □Australia
 - 14.5.4.6. □ASEAN
 - 14.5.4.7. □Rest of Asia-Pacific
- 14.6. □Middle East & Africa NK Cell Therapeutics Market Analysis and Forecast 2019-2028
 - 14.6.1. □Regional Market Overview and Key Takeaways
 - 14.6.2. □Middle East & Africa NK Cell Therapeutics Market by Application
 - 14.6.3. □Middle East & Africa NK Cell Therapeutics Market by End User
 - 14.6.4. □Middle East & Africa NK Cell Therapeutics Market by Country
 - 14.6.4.1. □GCC
 - 14.6.4.2. □South Africa
 - 14.6.4.3. □Turkey
 - 14.6.4.4. □Rest of the Middle East & Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15. Competitive Landscape
 - 15.1. Competition Dashboard
 - 15.1.1. Global and Regional Market Share Analysis
 - 15.1.2. Market Structure
 - 15.2. Competitive Benchmarking
 - 15.3. Key Strategy Analysis
 - 15.4. Company Profiles
 - 15.4.1. Affimed GmbH
 - 15.4.1.1. Company Overview
 - 15.4.1.2. Application/Service Offerings
 - 15.4.1.3. Key Financials
 - 15.4.1.4. Recent Developments
 - 15.4.2. Bristol-Myers Squibb Company
 - 15.4.2.1. Company Overview
 - 15.4.2.2. Application/Service Offerings
 - 15.4.2.3. Financials
 - 15.4.2.4. Recent Developments
 - 15.4.3. Nkarta Inc.
 - 15.4.3.1. Company Overview
 - 15.4.3.2. Application/Service Offerings
 - 15.4.3.3. Financials
 - 15.4.3.4. Recent Developments
 - 15.4.4. Zelluna Immunotherapy AS
 - 15.4.4.1. Company Overview
 - 15.4.4.2. Application/Service Offerings
 - 15.4.4.3. Financials
 - 15.4.4.4. Recent Developments
 - 15.4.5. XNK Therapeutics AB
 - 15.4.5.1. Company Overview
 - 15.4.5.2. Application/Service Offerings
 - 15.4.5.3. Financials
 - 15.4.5.4. Recent Developments
 - 15.4.6. ONK Therapeutics
 - 15.4.6.1. Company Overview
 - 15.4.6.2. Application/Service Offerings
 - 15.4.6.3. Financials
 - 15.4.6.4. Recent Developments
 - 15.4.7. Catamaran Bio
 - 15.4.7.1. Company Overview
 - 15.4.7.2. Application/Service Offerings
 - 15.4.7.3. Financials
 - 15.4.7.4. Recent Developments
 - 15.4.8. MiNK Therapeutics
 - 15.4.8.1. Company Overview
 - 15.4.8.2. Application/Service Offerings
 - 15.4.8.3. Financials
 - 15.4.8.4. Recent Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.4.9. Takeda Pharmaceutical Company Limited

15.4.9.1. Company Overview

15.4.9.2. Application/Service Offerings

15.4.9.3. Financials

15.4.9.4. Recent Developments

15.4.10. Celularity Inc.

15.4.10.1. Company Overview

15.4.10.2. Application/Service Offerings

15.4.10.3. Financials

15.4.10.4. Recent Developments

15.4.11. Artiva Biotherapeutics

15.4.11.1. Company Overview

15.4.11.2. Application/Service Offerings

15.4.11.3. Financials

15.4.11.4. Recent Developments

A comprehensive list of NK cell therapeutics providers will be provided along with geographical reach, employee count, revenue, product capacities, and their capabilities

16. Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Natural Killer (NK) Cell Therapeutics Market: Investment & Growth Opportunity Analysis, 2019-2028

Market Report | 2022-09-01 | 120 pages | RationalStat

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4570.00
	Multi User License	\$6220.00
	Corporate License	\$7870.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

